Budget Impact Analysis of Fixed Dose Versus Weight-Based Dosing Regimen of Nivolumab and Pembrolizumab in the Treatment of Non-Small Cell Lung Cancer

Budget Impact Analysis of Fixed Dose Versus Weight-Based Dosing Regimen of Nivolumab and Pembrolizumab in the Treatment of Non-Small Cell Lung Cancer

In 2018, dosing regimens of the two most prescribed immune check point inhibitors (ICI), nivolumab (Opdivo<sup>®</sup>) and pembrolizumab (Keytruda<sup>®</sup>), in the treatment of lung cancer were changed from weight-based dosing to fixed dosing. The aim of this study was t...

Full description

Bibliographic Details
Main Authors: Sanjana Monirul, Marthe Rigal, Kader Chouahnia, Mélisande Le Jouan, Maxime Apparuit, Adrien Paix, Anne Jacolot, Laurent Zelek, Boris Duchemann
Format: Article
Language:English
Published: MDPI AG 2020-12-01
Series:Vaccines
Subjects:
budget impact analysis
lung cancer
nivolumab
pembrolizumab
fixed dose
cancer immunotherapy
Online Access:https://www.mdpi.com/2076-393X/8/4/730

Internet

https://www.mdpi.com/2076-393X/8/4/730

Similar Items